{"prompt": "['Cycle 2 and followings', 'Day 1', 'Day 15', 'Day 29', 'Cyclophosphamide', '50 mg/die continuous', 'Day 1, 15 Avelumab 10 mg/kg', 'Day 29 Day 1 following cycles', '5.0 SELECTION CRITERIA', '5.1 Inclusion Criteria', 'In order to be eligible for participation in this trial, the subject must:', '1. Be willing and able to provide written informed consent for the trial. The subject may also', 'provide consent for the translational study.', '2. Be > 18 years of age on day of signing informed consent.', '3. ECOG Performance Status 0-2.', '4. Have histologically or cytologically-confirmed recurrent or metastatic (disseminated) head', 'and neck squamous cell carcinoma', '5. Have a disease progression after treatment with at least one line of therapy including at least', 'Cisplatin, Fluorouracil and Cetuximab for recurrent (disease not amenable to curative', 'treatment)/metastatic disease.', '6. Measurable disease by RECIST criteria.', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '19']['7. At least one metastatic site suitable for irradiation', '8. Life expectancy > 3 months.', '9. Adequate bone marrow function: neutrophils > 1.5 x 10%/L, platelets > 100 X 10%/L,', 'hemoglobin >9 g/dL.', '10. Adequate liver function: AST and ALT levels VI 2.5 X ULN; bilirubin < 1.5 X ULN.', '11. Adequate renal function: creatinine clearance > 30 mL/min (Cockroft-Gault)', '12. Fertil men must be using adequate contraceptive measures throughout the study period if', 'their partner are women of childbearing potential.', '13. If of childbearing potential, women must use effective contraceptive method (Pearl Index <', '1; e.g. oral contraceptive (pill), hormone spiral, hormone implant, transdermal patch, a', 'combination of two barrier methods (condom and diaphragm), sterilisation, sexual', 'abstinence) for the study duration and for at least 6 months after last avelumab treatment', 'administration if the risk of conception exists.', '5.2 Exclusion Criteria', '1. History of malignant disease (with the exception of non-melanoma skin tumours and/or in', 'situ cervical cancer) in the preceding five years.', '2. Brain metastases.', '3. Autoimmune disorders. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or', 'hyperthyroid diseases not requiring immunosuppressive treatment are eligible.', '4. Allergic disorders.', '5. Cyclophosphamide treatment contraindications:', 'a. Cystitis.', 'b. Urinary Obstruction.', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '20']['c. Inadequate bone marrow function: WBC <2900 mm3 and/or HCT <30% and/or platelets', 'count <90000 mm3.', 'd. Active infections.', 'e, Pregnancy or breast feeding.', '6. Prior treatment with inhibitors of the PD-L1 - PD - 1 axis or inhibitors of CTLA-4 (immune', 'check point inhibitors)', '7. Previous HBV or HCV infections.', '8. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,', 'inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b, Systemic', 'corticosteroids at physiologic doses < 10 mg/day of prednisone or equivalent; c. Steroids as', 'premedication for hypersensitivity reactions (e.g., CT scan premedication).', '9. Any active infection requiring specific treatment (Antibiotics, antimicotic, antiviral).', '10. Radiotherapy within 6 weeks before enrolment', '11. Other non-malignant uncontrolled systemic diseases or social conditions that would', 'preclude trial entry in the opinion of the investigator.', '12. Prior organ transplantation including allogenic stem-cell transplantation.', '13. Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited', 'except for administration of inactivated vaccines.', '14. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,', 'alopecia, sensory neuropathy Grade  2, or other Grade VI 2 not constituting a safety risk', \"based on investigator's judgment are acceptable.\", '15. Other severe acute or chronic medical conditions including colitis, inflammatory bowel', 'disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within', 'the past year) or active suicidal ideation or behaviour: or laboratory abnormalities that may', 'increase the risk associated with study participation or study treatment administration or', 'CONFRONT Study v. 1,1 del 07/05/2018 - Study Protocol', '21']\n\n###\n\n", "completion": "END"}